Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, has announced its participation in the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference. Jonathan Collins, Executive Vice President and Chief Financial Officer, will present on Monday, August 12, 2024, at 2:55 pm Eastern Time.
Investors and interested parties can access the live webcast of the presentation through a provided link. A replay of the webcast will be available on Clarivate's investor relations website for 90 days following the event. This presentation offers an opportunity for stakeholders to gain insights into Clarivate's current position and future strategies in the technology and information services sector.
Clarivate Plc (NYSE: CLVT) has announced a significant leadership change. Matti Shem Tov, former CEO of ProQuest, will become the company's new CEO effective August 9, 2024, replacing Jonathan Gear. Shem Tov will also join the Board of Directors. Gear will transition to a non-executive role until November 1, 2024.
The Board and Gear mutually agreed on this transition, aiming to take Clarivate into its next phase of value creation. Under Gear's leadership, Clarivate restructured into three end-market segments, enhanced product innovation, and strengthened its balance sheet. The company is now positioned to leverage expertise within each business segment to deliver tailored solutions globally.
Shem Tov's appointment is expected to accelerate Clarivate's organic growth, leveraging his experience in product innovation and market delivery. The change comes as Clarivate reported its second quarter 2024 results.
Clarivate (NYSE: CLVT) reported its Q2 2024 financial results, showing a 2.8% revenue decrease to $650.3 million. Organic revenues dipped 0.6%, with an increase of 0.7% in subscription revenues offset by declines in re-occurring and transactional revenues.
The company posted a net loss of $304.3 million, with adjusted net income down 6.6% to $142.2 million. Adjusted diluted EPS fell 4.8% to $0.20. Adjusted EBITDA decreased by 3.7% to $274.4 million, with a margin contraction to 42.2%.
For the six months ending June 30, 2024, revenues totaled $1.27 billion, a 2% decline. Net loss for this period was $379.3 million, and adjusted net income dropped 13.2% to $245.7 million. Adjusted diluted EPS was down 12.8% to $0.34. Adjusted EBITDA was $510.7 million, a 5% decrease.
Free cash flow plummeted by $44.5 million in Q2 to $60.3 million and by $100.9 million for the first half of the year to $172.1 million.
The company reaffirmed its 2024 outlook and highlighted new product launches and positive customer responses.
Clarivate Plc (NYSE:CLVT) has launched the new OFF-X™ platform, an enhanced solution for preclinical and clinical safety intelligence in biopharma. The platform offers a seamless user experience and unique translational insights, delivering important drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ provides a comprehensive resource for safety information, streamlining processes and enhancing efficiency.
Key improvements include an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events, faster search capabilities, clearer visual design, full-screen visualization, and additional analytic tools. The platform empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug R&D and post-marketing.
Clarivate Plc (NYSE: CLVT) has announced that Richard Roedel will retire from its Board of Directors on December 31, 2024, due to health reasons. Valeria Alberola, a board member since May 2021, is expected to succeed Roedel as Chair of the Audit Committee. Alberola brings over 25 years of global experience in corporate finance, investment banking, sustainable investments, operations, and strategic management consulting.
Alberola previously served as CEO of Zoma Holdings, from January 2019 to March 2024, following her role as COO from 2017 to 2018. She has also held positions as CFO of Bridge Education Group, Inc. and partner at Q Advisors Alberola holds a B.S. in Economics and Business Administration and an M.B.A. from the Kellogg School of Management at Northwestern University.
Clarivate Plc (NYSE: CLVT) has acquired Rowan TELS Corp., the provider of Rowan Patents, an integrated patent drafting and prosecution solution. This strategic move aims to enhance Clarivate's workflow automation solutions beyond its current IP management and intelligence capabilities. The acquisition will enable Clarivate to offer comprehensive, AI-enabled solutions for patent preparation, filing, and prosecution.
The integration of Rowan Patents will help Clarivate advance its strategy to become the central hub for IP management, providing an end-to-end workspace for patent practitioners. This aligns with Clarivate's commitment to simplifying and optimizing IP management in an increasingly competitive global market.
BioWorld, published by Clarivate Plc (NYSE:CLVT), has been honored with nine 2024 APEX Awards for Publication Excellence. This achievement highlights BioWorld's commitment to delivering superior journalistic excellence, data-driven analysis, and cutting-edge digital publishing in the life sciences and healthcare sector.
The awards span various categories, including writing, news, mental health, financial/investment, and economics. Notable wins include Grand Awards in the Writing Category for articles on sepsis testing and spinal cord injury treatment. The recognition underscores BioWorld's leadership in providing important insights into therapeutics development, medical technologies, business deals, and regulatory challenges.
These accolades reflect the BioWorld team's dedication to producing award-winning journalism that resonates with readers and the publishing industry, reinforcing its position as a leader in delivering critical information that drives innovation and improves lives worldwide.
Clarivate Plc (NYSE:CLVT) has announced a partnership with OhioLINK and SearchOhio to develop a new unified library resource sharing experience across Ohio. The collaboration aims to integrate OhioLINK and SearchOhio's existing INN-Reach platforms into a single consortial solution, expected to be implemented by mid-2025.
The new system will provide a seamless user experience for accessing library materials from 45 public library systems and 87 institutions statewide. It will offer an intuitive interface for patrons to discover resources and explore new content, potentially improving learning outcomes. This initiative builds on OhioLINK's 30-year history of leveraging technology for educational support and SearchOhio's commitment to enhancing public library services.
Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, before the market opens. The company will release a press release and earnings supplement with financial information on its investor website. Additionally, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to review the results. The webcast will be open to all interested parties and may include forward-looking statements.
Clarivate Plc (NYSE:CLVT) has released its annual G20 scorecard, analyzing research and innovation trends across G20 members. The 2024 report, compiled by the Institute for Scientific Information, includes interactive data visualizations and, for the first time, data for the European Union and African Union. Key findings highlight:
- African Union's high collaboration rate and focus on SDGs 1 and 5
- European Union as the largest contributor of papers
- Germany's above-average citation impact and open access publishing
- India's increasing international collaboration
- Mainland China's shifting collaboration patterns
- South Korea's rising collaborations with China and India
- UK's high citation impact and strong international collaboration
- US's strong patent citation impact in various fields
The scorecard aims to provide a comprehensive view of the global research landscape, informing policymakers and research institutions for strategic decision-making.